This shows you the differences between two versions of the page.
Both sides previous revisionPrevious revisionNext revision | Previous revisionNext revisionBoth sides next revision | ||
home:mp [03.13.2019] – [Stopping olmesartan] sallieq | home:mp [04.02.2020] – [Marshall Protocol] sallieq | ||
---|---|---|---|
Line 3: | Line 3: | ||
====== Marshall Protocol ====== | ====== Marshall Protocol ====== | ||
+ | |||
+ | < | ||
This document is a one-article summary of key issues related to the Marshall Protocol, especially those relevant to physicians. | This document is a one-article summary of key issues related to the Marshall Protocol, especially those relevant to physicians. | ||
Line 250: | Line 252: | ||
Olmesartan will need to be [[home: | Olmesartan will need to be [[home: | ||
- | ==== Data ==== | ||
- | |||
- | [[home: | ||
{{tag>MP summary}} | {{tag>MP summary}} | ||
+ | ===== Data ===== | ||
+ | |||
+ | [[home: | ||
+ | |||
+ | [[home: | ||
+ | |||
+ | ==== Recovery figures ==== | ||
+ | |||
+ | | ||
+ | |||
+ | SUCCESS RATES: Over all success rate 66.32% Over all unsuccessful 13.77% Over all unsure 19.91% | ||
+ | |||
+ | Sarcoidosis success 75.8% | ||
+ | |||
+ | Chronic Fatigue Syndrome success 60.1% | ||
+ | |||
+ | Lyme disease success 66.9% | ||
+ | |||
+ | Rheumatoid arthritis success 69.2% | ||
+ | |||
+ | Fibromyalgia success 64.2% | ||
+ | |||
+ | All Other Th1 disease success 59.8% | ||
===== Notes and comments ===== | ===== Notes and comments ===== | ||